Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity (Q39705304)

14 September 2017

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity (English)

1 reference

14 September 2017

1 reference

Mariola Fotin-Mleczek

6

object named as

Mariola Fotin-Mleczek

1 reference

14 September 2017

7

Regina Heidenreich

1 reference

14 September 2017

Aleksandra Kowalczyk

1

1 reference

14 September 2017

Fatma Doener

2

1 reference

14 September 2017

Kai Zanzinger

3

1 reference

14 September 2017

Janine Noth

4

1 reference

14 September 2017

Patrick Baumhof

5

1 reference

14 September 2017

language of work or name

English

0 references

publication date

3 June 2016

1 reference

14 September 2017

12

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 September 2017

34

1 reference

14 September 2017

3882-3893

1 reference

14 September 2017

33

1 reference

Developing mRNA-vaccine technologies

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Delivery systems for gene-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Innate immunity and vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Master sensors of pathogenic RNA - RIG-I like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

mRNA-based therapeutics--developing a new class of drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Antigen availability determines CD8⁺ T cell-dendritic cell interaction kinetics and memory fate decisions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Proteolysis and cell migration: creating a path?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Cell type-specific involvement of RIG-I in antiviral response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

Antigen amount dictates CD8+ T-cell exhaustion during chronic viral infection irrespective of the type of antigen presenting cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.05.046

10.1016/J.VACCINE.2016.05.046

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference